Cytokines in cancer pathogenesis and cancer therapy

G Dranoff - Nature Reviews Cancer, 2004 - nature.com
The mixture of cytokines that is produced in the tumour microenvironment has an important
role in cancer pathogenesis. Cytokines that are released in response to infection …

GM-CSF: from growth factor to central mediator of tissue inflammation

B Becher, S Tugues, M Greter - Immunity, 2016 - cell.com
The granulocyte-macrophage colony-stimulating factor (GM-CSF) was initially classified as a
hematopoietic growth factor. However, unlike its close relatives macrophage CSF (M-CSF) …

A history of prostate cancer treatment

SR Denmeade, JT Isaacs - Nature Reviews Cancer, 2002 - nature.com
The increased incidence of prostate cancer has led to remarkable changes in diagnosis and
treatment over the past century. What were the first ways in which prostate cancer was …

[HTML][HTML] Immunotherapy for colorectal cancer

S Koido, T Ohkusa, S Homma, Y Namiki… - World journal of …, 2013 - ncbi.nlm.nih.gov
The incidence of colorectal cancer (CRC) is on the rise, and the prognosis for patients with
recurrent or metastatic disease is extremely poor. Although chemotherapy and radiation …

Novel allogeneic granulocyte-macrophage colony-stimulating factor–secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

EM Jaffee, RH Hruban, B Biedrzycki… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: Allogeneic granulocyte-macrophage colony-stimulating factor (GM-CSF)–
secreting tumor vaccines can cure established tumors in the mouse, but their efficacy …

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

P Serafini, R Carbley, KA Noonan, G Tan, V Bronte… - Cancer research, 2004 - AACR
Tumor vaccines have shown promise in early clinical trials. Among them, tumor cells
genetically engineered to secrete biologically active granulocyte-macrophage colony …

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell …

JPH Machiels, RT Reilly, LA Emens, AM Ercolini… - Cancer research, 2001 - AACR
Tumor-specific immune tolerance limits the effectiveness of cancer vaccines. In addition,
tumor vaccines alone have a limited potential for the treatment of measurable tumor …

A potential role of macrophage activation in the treatment of cancer

AH Klimp, EGE De Vries, GL Scherphof… - Critical reviews in …, 2002 - Elsevier
One of the functions of macrophages is to provide a defense mechanism against tumor cells.
In the last decades the mechanism of tumor cell killing by macrophages have been studied …

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade

AA Hurwitz, BA Foster, ED Kwon, T Truong, EM Choi… - Cancer research, 2000 - AACR
We have previously shown that antibodies to CTLA-4, an inhibitory receptor on T cells, can
be effective at inducing regression of transplantable murine tumors. In this study, we …

Past, current, and future of immunotherapies for prostate cancer

AN Boettcher, A Usman, A Morgans… - Frontiers in …, 2019 - frontiersin.org
Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of
cancer related death in men in Western countries. The standard therapy for metastatic PCa …